GE HealthCare issues $1.5 billion in senior notes

GE HealthCare (GEHC) has announced the issuance of $1.5 billion in senior unsecured notes, consisting of $650 million in 4.800% notes due 2031 and $850 million in 5.500% notes due 2035, ranking equally with existing senior unsecured debt. This debt issuance follows a strong Q1 2025 performance, including 4% organic revenue growth to $4.8 billion and a 12% adjusted EPS increase to $1.01, alongside a record backlog of $20.6 billion. The company projects 2-3% organic revenue growth and adjusted EPS of $3.90-$4.10 for full-year 2025.

Analysis

GE HealthCare Technologies Inc. (GEHC) has announced the issuance of $1.5 billion in senior unsecured notes, consisting of $650 million in 4.800% notes due 2031 and $850 million in 5.500% notes due 2035. This debt issuance, ranking pari passu with existing senior unsecured obligations, is part of the company's ongoing capital management strategy and occurs while GEHC maintains a debt-to-equity ratio of 1.0 and an InvestingPro "GOOD" financial health score. The timing is notable following a robust first quarter of 2025, where GEHC reported $4.8 billion in revenue, representing 4% year-over-year organic growth, and a 12% increase in adjusted earnings per share to $1.01. Further bolstering this positive operational picture is a record backlog of $20.6 billion, indicative of strong demand in key U.S. and European markets. For the full year 2025, GE HealthCare projects organic revenue growth between 2% and 3% and an adjusted EPS in the range of $3.90 to $4.10. Strategic initiatives, such as the launch of a new PET imaging agent and active efforts to mitigate tariff impacts, underscore the company's proactive stance on market expansion and operational efficiency. InvestingPro's assessment that GEHC's stock may be trading below its fair value adds a compelling valuation angle to these developments.

Key Decisions for Investors

• Investors should evaluate GE HealthCare's $1.5 billion senior note issuance within the context of its solid Q1 2025 financial results, including 4% organic revenue growth and a 12% adjusted EPS increase, and its 'GOOD' financial health rating, suggesting the new debt is manageable.
• The company's full-year 2025 guidance for 2-3% organic revenue growth and adjusted EPS of $3.90-$4.10, supported by a record $20.6 billion backlog and ongoing product innovation, should be closely monitored for signs of continued execution and potential market outperformance.
• Given InvestingPro's indication that GEHC stock might be undervalued, coupled with a 'strongly positive' sentiment signal and proactive strategic initiatives, investors could consider current market conditions as an opportunity for further due diligence or to assess entry or accumulation strategies, while remaining cognizant of efforts to mitigate tariff impacts.